Trump's MFN drug-pricing expansion to 26 companies covering 89 percent of the branded drug market splits healthcare ETF outlook between providers and drugmakers.
Back
Trump's MFN drug deals cover 89% of market, splitting healthcare ETFs
A bifurcated trade is emerging across healthcare exchange-traded funds as the White House's drug-pricing framework now reaches 26 manufacturers and roughly nine of every ten dollars spent on branded medicines in the United States.
The latest round adds nine largely foreign-headquartered drugmakers — Alcon of Switzerland, Astellas of Japan, CSL of Australia, Kyowa Kirin of Japan, Sun Pharma of India, Teva of Israel and UCB of Belgium among them — to a Most-Favored-Nation structure that began with 17 of the world's largest pharmaceutical companies including Pfizer, Eli Lilly and Amgen, according to the White House.
"The expansion of Trump's MFN agreements is a mixed development rather than a straightforward positive or negative for healthcare stocks," according to Zacks Investment Research, which analyzed the framework's implications for exchange-traded funds tracking the sector.
The agreements primarily target Medicaid and certain consumer drug purchases, leaving employer-sponsored insurance plans largely outside their direct scope. That carve-out shapes the sector's ETF landscape: the iShares U.S. Healthcare Providers ETF (IHF) has inched up 0.6 percent over the past week as investors weigh whether lower prescription-drug costs will improve insurers' pharmacy and medical expense lines.
Lower drug prices could reduce insurers' medical-loss ratios if premiums and reimbursement rates hold steady, benefiting providers and government-sponsored health plans. But the trade-off cuts both ways. If drug costs decline materially, policymakers may push for lower insurance premiums, transferring savings from insurers to consumers. Pharmacy-benefit managers embedded in the IHF ETF could also see rebate- and spread-based revenue streams shrink as list and net drug prices fall.
Drugmakers Face Margin Pressure With Policy Clarity
For pharmaceutical companies, the MFN framework does not eliminate pricing pressure — it provides greater clarity on how the administration plans to lower U.S. drug costs. Some companies may offset revenue losses through tariff relief and policy certainty tied to increased U.S. manufacturing commitments. The nine newest participants are predominantly international firms, suggesting the administration is using pricing leverage to reshape where drugs are produced.
The structural shift carries implications beyond individual stocks. Healthcare ETFs that track broad pharmaceutical indices face selective rebalancing as companies with heavy exposure to MFN-affected drugs see their weightings and valuations adjust. Diversified funds that blend providers, insurers and drugmakers may see the policy's effects net out, while specialized funds tilt toward whichever segment the market judges the relative winner.
What Comes Next
The next phase of the MFN rollout will determine how far pricing pressure extends. If the administration pushes agreements into employer-sponsored plans — the largest remaining pool of commercial drug spending — the impact on pharmaceutical margins would deepen considerably. For now, the framework's expansion to 26 companies signals that drug pricing will remain a structural headwind for pharma valuations through the remainder of the administration's term.
This article is for informational purposes only and does not constitute investment advice.
